Cone-rod dystrophy
MONDO:0015993Inherited retinal dystrophies that belong to the group of pigmentary retinopathies.
Also known as: CRD, cone rod dystrophy
45 clinical trials for this condition and its sub-types, 17 tagged with Cone-rod dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cone-rod dystrophy
-
X-linked cone-rod dystrophy 0 trials · 2 incl. sub-types
4 sub-types
- Blue cone monochromacy 2 trials
- X-linked cone-rod dystrophy 1 0 trials
- X-linked cone-rod dystrophy 2 0 trials
- X-linked cone-rod dystrophy 3 0 trials
-
Cone-rod dystrophy 10 1 trial
-
Cone-rod dystrophy 6 1 trial
-
Leber congenital amaurosis 4 0 trials
-
Newfoundland cone-rod dystrophy 0 trials
-
Cone dystrophy 3 0 trials
-
Cone-rod dystrophy 1 0 trials
-
Cone-rod dystrophy 11 0 trials
-
Cone-rod dystrophy 12 0 trials
-
Cone-rod dystrophy 13 0 trials
-
Cone-rod dystrophy 14 0 trials
-
Cone-rod dystrophy 15 0 trials
-
Cone-rod dystrophy 16 0 trials
-
Cone-rod dystrophy 17 0 trials
-
Cone-rod dystrophy 18 0 trials
-
Cone-rod dystrophy 19 0 trials
-
Cone-rod dystrophy 2 0 trials
-
Cone-rod dystrophy 20 0 trials
-
Cone-rod dystrophy 21 0 trials
-
Cone-rod dystrophy 22 0 trials
-
Cone-rod dystrophy 24 0 trials
-
Cone-rod dystrophy 3 0 trials
-
Cone-rod dystrophy 5 0 trials
-
Cone-rod dystrophy 7 0 trials
-
Cone-rod dystrophy 8 0 trials
-
Cone-rod dystrophy 9 0 trials
-
Retinal cone dystrophy 4 0 trials
-
One-Time eye injection could slow blindness in retinitis pigmentosa
Disease control OngoingThis study tests a gene therapy called SPVN06 for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment is given as a single injection under the retina. The trial includes 33 adults with advanced disease and will check safety and whether it…
Phase 1/2 • Sponsor: SparingVision • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
Disease control OngoingThis early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal …
Phase 1/2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Spinal zaps and exercise may boost walking after injury
Symptom relief OngoingThis study tests whether combining motor skill training with a non-invasive spinal stimulation can improve walking, balance, and strength while reducing muscle spasticity in people with incomplete spinal cord injury. Twenty-eight participants will do a series of standing exercise…
Sponsor: Shepherd Center, Atlanta GA • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC